Oral GLP-1 Orforglipron Cuts Sleep Apnea Events, Cardiovascular Risk Factors in Year-Long Trials
Found this article helpful?
Share it with your network and spread the knowledge!

Adults with moderate-to-severe sleep apnea and excess weight experienced about 18 fewer breathing interruptions per hour of sleep after taking the daily oral GLP-1 medication orforglipron for one year, compared with about 5 fewer interruptions among those on placebo, according to late-breaking science presented at the American Heart Association's Scientific Sessions 2026 in Chicago and simultaneously published in JAMA. The findings, from the ATTAIN-OSA trials, are the first large trials of an oral medication for obstructive sleep apnea in people with overweight or obesity, and they carry significant implications for Texas, where cardiovascular disease and metabolic conditions remain leading health concerns.
The two year-long trials enrolled 712 adults with moderate-to-severe sleep apnea and a body mass index of 27 kg/m² or higher. Study 1 included 363 participants who did not use continuous positive airway pressure (CPAP) therapy, while Study 2 included 349 current CPAP users who paused therapy for seven days before sleep testing. Half of each group received orforglipron and half received placebo. After 52 weeks, participants taking orforglipron also had greater reductions in body weight (about 10-11% vs. 1-2% with placebo), in high-sensitivity C-reactive protein, a marker of inflammation (-42% vs. -4% in Study 1 and -38% vs. -18% in Study 2), and in systolic blood pressure (about -7.5 vs. -1.7 mm Hg in Study 1 and -7.0 vs. -2.2 mm Hg in Study 2). Sleep apnea-related drops in blood oxygen levels improved by 51% and 44% in the two studies, respectively, compared with 18% in both placebo groups.
"Untreated moderate to severe sleep apnea frequently goes hand in hand with high blood pressure, which can strain the heart and blood vessels over time, leading to increased risk of heart disease and stroke," said presenting author Vaishnavi Kundel, M.D., M.Sc., associate professor of medicine at the Icahn School of Medicine at Mount Sinai. "Even a modest decrease in blood pressure can help protect a patient's heart and overall health." She noted that while CPAP use can lower blood pressure by about two to three points, the seven-point reduction seen with orforglipron represents a meaningful cardiovascular benefit for people with sleep apnea.
The medication is not intended to replace CPAP therapy but could expand treatment options, particularly for patients who cannot tolerate or choose not to use CPAP devices. "A convenient daily pill may help expand access to treatment for sleep apnea, and it could potentially be used with CPAP or other therapies to better meet individual patient's needs," Kundel said. The most common side effects were nausea, diarrhea and constipation, reported as mostly mild to moderate. The studies were funded by Eli Lilly and Company and conducted at 66 medical centers across North America, South America, Europe and Asia. Researchers noted limitations including a one-year follow-up and the exclusion of people with diabetes or mild sleep apnea.
The results also reinforce the American Heart Association's inclusion of healthy sleep in its Life's Essential 8 metrics, a checklist that emphasizes sleep as a component of cardiovascular health. For Texas employers and health systems, the findings suggest a potential new tool for managing a condition that affects an estimated 1 billion adults worldwide and is closely tied to obesity, hypertension and stroke risk. The full release is available via www.newmediawire.com, and additional heart health resources can be found at heart.org and stroke.org.
